Netherton Syndrome
4
Pipeline Programs
4
Companies
5
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
0
1
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Boehringer IngelheimINGELHEIM, Germany
2 programs1
Spesolimab - solution for infusionPhase 2/31 trial
Natural History of Netherton SyndromeN/A1 trial
Active Trials
DS
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
Boehringer IngelheimSpesolimab - solution for infusion
Daiichi SankyoDS-2325a
BioCryst PharmaceuticalsBCX17725
AzitraATR12-351
Boehringer IngelheimNatural History of Netherton Syndrome
Clinical Trials (5)
Total enrollment: 142 patients across 5 trials
A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome
Start: Jun 2023Est. completion: Jul 202543 patients
Phase 2/3Terminated
A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome
Start: Sep 2023Est. completion: Jan 20259 patients
Phase 1/2Terminated
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
Start: Sep 2024Est. completion: Dec 202678 patients
Phase 1Recruiting
Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome
Start: Jun 2024Est. completion: Aug 2026
Phase 1Recruiting
Natural History of Netherton Syndrome
Start: Oct 2024Est. completion: Mar 202512 patients
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 142 patients
4 companies competing in this space